ABEMACICLIB

Brand name:

• Verzenio™

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Breast cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to PBS listing (Standard Re-entry Pathway)

Comment:

No further action, please see ABEMACICLIB link in Related medicines below.

Submission sponsor:

Eli Lilly Australia Pty Ltd

Other PBAC consideration:

• ABEMACICLIB
• ABEMACICLIB
• ABEMACICLIB

Submission received for:

March 2023 PBAC meeting

Opportunity for consumer comment:

Open 23/11/2022 and close 25/01/2023 (see PBS Website)

PBAC meeting:

Held on 08/03/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

28/04/2023

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---